Results 91 to 100 of about 5,090 (179)

Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook

Vaccines
Oncolytic virus (OV) immunotherapy, particularly with oncolytic herpes simplex virus (oHSV), has become a promising new strategy in cancer treatment. This field has achieved significant clinical milestones, highlighted by the FDA approval of Talimogene ...
Yiyang Zheng, Yusheng Pei, Chunyan Dong, Jinghui Liang, Tong Cai, Yuan Zhang, Dejiang Tan, Junzhi Wang, Qing He   +8 more
doaj   +1 more source

Virotherapy: cancer gene therapy at last? [version 1; referees: 2 approved]

F1000Research, 2016
For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach.
Alan E. Bilsland, Pavlina Spiliopoulou, T. R. Jeffry Evans   +2 more
doaj   +1 more source

Developments in the treatment of advanced melanoma [PDF]

, 2017
Ontwikkelingen in de behandeling van lokaal gevorderd en uitgezaaid melanoomPatiënten met melanoom ≥1 mm dik ondergaan een schildwachtklierprocedure, waarbij de eerste lymfeklier, waarheen kankercellen uitzaaien wordt verwijderd en onderzocht op ...
Sloot, Sarah
core   +4 more sources

Where are we now with oncolytic viruses in melanoma and nonmelanoma skin malignancies? [PDF]

Skin cancer prognosis has greatly improved recently due to the introduction of immune checkpoint inhibitors (ICIs). However, many patients with advanced skin cancer still experience immunotherapy resistance and disease progression during ICI treatment ...
Anaeme, Angela, Ansstas, George, Chen, David, Moussa, Karen, Nassief, George   +4 more
core   +2 more sources

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy

Biologics: Targets & Therapy, 2018
Kenneth Lundstrom PanTherapeutics, Lutry, Switzerland Abstract: Oncolytic viruses have demonstrated selective replication and killing of tumor cells.
Lundstrom K
doaj  

Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma

Journal for ImmunoTherapy of Cancer
Adult T-cell leukemia/lymphoma (ATLL), an aggressive T-cell malignancy associated with human T-cell leukemia virus type 1, presents significant therapeutic challenges due to high relapse rates and resistance to therapy.
Qiang Liu, Yanhua Wang, Yang Shi, Amit Verma, Qing Wang, Wei Cai, Wenjun Deng, Haiying Cheng, Rafi Kabarriti, Jianhong An, Erqiang Hu, Yanan Fang, Naijia Liu, Wu He, Angelina Wang, Yinghui Song, Jidong Shan, Jinghang Zhang, Yiyu Zou, Roberto Alejandro Sica, Shanye Yin   +20 more
doaj   +1 more source

Immunotherapy for head and neck squamous cell carcinoma [PDF]

, 2016

core   +1 more source

Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential

Frontiers in Microbiology
BackgroundHead and neck squamous cell carcinoma remains a significant global health burden, particularly in low-resource regions like India. Conventional treatments often fall short in achieving durable responses, prompting the need for novel therapies ...
Aditi Gupta, Samiran Ranjit Chavan, Ravisekhar Gadepalli, Puneet Pareek   +3 more
doaj   +1 more source

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy. [PDF]

J Clin Med, 2023
Zhang T, Jou TH, Hsin J, Wang Z, Huang K, Ye J, Yin H, Xing Y.   +7 more
europepmc   +1 more source

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial [PDF]

, 2014

core   +1 more source